A 2026 partnering scan of Curigin, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Cellerant Therapeutics, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Eledon Pharmaceuticals, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Edesa Biotech, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Chimeric Therapeutics Limited, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of GEn1E Lifesciences, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Galectin Therapeutics Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of AndroScience, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of AIkido Pharma Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Gliknik, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Epsilon Molecular Engineering, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
A 2026 partnering scan of Arno Therapeutics, Inc, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.